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Abstract Ghrelin, a natural ligand for the growth hormone
(GH)-secretagogue receptor, is primarily produced in the
stomach. Administration of ghrelin stimulates food intake
and GH secretion in both animals and humans. Ghrelin is
the only circulating hormone known to stimulate appetite in
humans. As GH is an anabolic hormone, protein stores are
spared at the expense of fat during conditions of caloric
restriction. Ghrelin also inhibits the production of anorectic
proinflammatory cytokines. Thus, ghrelin exhibits anti-
cachectic actions via both GH-dependent and -independent
mechanisms. Several studies are evaluating the efficacy of
ghrelin in the treatment of cachexia caused by a variety of
diseases, including congestive heart failure, chronic obstruc-
tive pulmonary disease, cancer, and end-stage renal disease.
These studies will hopefully lead to the development of novel
clinical applications for ghrelin in the future. These studies
have also facilitated a better understanding of the molecular
basis of the anti-catabolic effects of ghrelin. This review
summarizes the recent advances in this area of research.
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1 Introduction
Ghrelin is a natural ligand for the growth hormone (GH)-
secretagogue receptor (GHS-R), which possesses a unique
fatty acid modification, an n-octanoylation, at Ser 3 [1]. Of
the two circulating forms of ghrelin, acylated and unacylated
(des-acyl), the acylated form is essential for the biological
activity of ghrelin acting via the GHS-R. Ghrelin plays a
critical role in a variety of physiological processes, including
the stimulation of GH secretion and regulation of energy
homeostasis by stimulating food intake and promoting
adiposity via a GH-independent mechanism [2–4]. GH,
which regulates insulin-like growth factor (IGF)-I levels, is
an anabolic hormone that spares protein stores at the expense
of fat utilization during conditions of caloric restriction. GH
and IGF-1 are the major mediators of metabolism involved in
the regulation of energy balance. Ghrelin inhibits the
production of anorectic proinflammatory cytokines, including
interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α
[5, 6]. The combination of these actions suggests this peptide
has benefits for the treatment of cachexia (Fig. 1).
Cachexia is defined as a complex metabolic syndrome
associated with underlying illness and characterized by loss of
muscle with or without loss of fat mass [7]. The prominent
clinical feature of cachexia is weight loss in adults (corrected
for fluid retention) or growth failure in children (excluding
endocrine disorders). Anorexia, inflammation, insulin resis-
tance, and increased muscle protein breakdown are frequently
associated with cachexia. Cachexia is distinct from starva-
tion, age-related loss of muscle mass, primary depression,
malabsorption, and hyperthyroidism and is associated with
increased morbidity. Recently, several trials attempting to
treat cachexia of different etiologies with ghrelin have been
expanded. This review summarizes the recent advances in
this area of research.
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2.1 Orexigenic action
Ghrelin has a well-established role in stimulating appetite
a n di n c r e a s i n gf o o di n t a k e[ 8, 9]; peripheral administra-
tion of ghrelin stimulates GH secretion and food intake in
both animals and humans [10, 11]. Ghrelin is the only
hormone known to stimulate appetite after peripheral
administration. Ghrelin, which increases c-fos expression
in the arcuate nucleus, also activates hypothalamic
neuropeptide Y/Y1 receptors and agouti-related peptide
pathways [12–14]. In addition, ghrelin induces food intake
via the orexin pathway [15]. These functions are mediated
at least in part by vagal nerve pathways [16]. Repeated
administration of ghrelin resulted in significant weight
gain in rats [17] and patients with chronic obstructive
pulmonary disease (COPD) [18]. Increases in adiposity
were associated with body weight gain in animal experi-
ments [17, 19, 20], while adiposity decreased in humans
[21–23]. This discrepancy may result from the differences
in the doses and frequencies of ghrelin administration.
Long-term, twice-weekly injection with low-dose ghrelin
(40 μg/kg) significantly decreased fat mass in aged mice
[24]. While weekly food intake did not increase under
these conditions, ghrelin-induced GH secretion may have
contributed to low adiposity. In contrast, lean body mass
i n c r e a s e di nr o d e n t s[ 24, 25] and humans [18, 21–23]
following ghrelin administration. Also, lean body mass
increases following ghrelin mimetic administration [26,
27]. These effects, which reflect increases in muscle mass,
are promising for cachexia treatment, as losses in body
weight and sarcopenia are characteristic features of
cachexia.
2.2 Stimulation of GH secretion
Ghrelin strongly stimulates GH secretion in humans [28–
31], severalfold more potently than GHRH under similar
circumstances. Furthermore, ghrelin and GHRH synergisti-
cally increases GH release [30]. Ghrelin might also play a
role on GH release in a non-acute setting [32]. GH regulates
IGF-I levels, promotes anabolism, and increases muscle
strength [33, 34]. While GH enhances lipolysis, IGF-1
stimulates protein synthesis, myoblast differentiation, and
muscle growth. Recombinant GH is currently approved by
the U.S. Food and Drug Administration for use in HIV/
AIDS wasting, parenteral nutrition-dependent short bowel
syndrome, pediatric chronic kidney disease, and adult and
pediatric GH-deficiency states [35]. Pharmacological doses
of this agent, however, cause problematic side effects, such
as dose-related arthralgias, carpal-tunnel syndrome, pares-
thesias, insulin resistance, sodium retention, and peripheral
edema. In contrast, stimulation of GH production to
supraphysiological levels following ghrelin administration
has a paucity of side effects.
Ghrelin’s ability to increase circulating IGF-1 levels has
been demonstrated in human studies of congestive heart
failure (CHF) and COPD, in which 3-week ghrelin
injections tended to increase IGF-1 levels [18, 36]. This
effect is less evident as that seen for growth hormone
secretagogues (GHS), such as MK-677 and anamorelin
(RC-1291). Long-term treatment (6 months) with MK-677
in patients with hip fractures increased IGF-1 levels by 84%
in comparison to 17% after placebo [37]. Anamorelin
treatment induced impressive increases in food intake in a
12-week trial of cancer cachexia; post-treatment IGF-1
levels were 36.5 ng/mL after anamorelin treatment in
comparison to 5.95 ng/mL after placebo. In a 6-day trial
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to greater than 60 ng/mL after anamorelin treatment in
comparison to <0 ng/mL after placebo [38, 39]. In our
study of patients undergoing total hip replacement for
osteoarthritis, serum IGF levels changed significantly
following eight daily ghrelin injections; the changes in
post-treatment IGF-1 levels were 30.0 ng/mL for ghrelin in
comparison to 5.6 ng/mL for placebo. These changes were
not observed after 21 daily treatments. In males, however,
serum IGF-1 levels after ghrelin treatment remained
elevated in comparison to the placebo group. Thus, the
timing and duration of ghrelin injection and the subjects
receiving treatment (e.g., disease features and sex) may
influence the effect of ghrelin on IGF-1 levels. In addition,
serum levels of IGF-1, which is primarily produced by the
liver, reflect the systemic effects of IGF-1. GH also induces
the synthesis of IGF-I in non-hepatic tissues. The local
(autocrine/paracrine) effects of IGF-1 may play distinct
roles in various tissues, including muscle mass regulation
[34, 40]. For instance, local muscle-restricted IGF-1 trans-
gene expression accelerates the regeneration of injured
skeletal muscle in mice, modulating inflammatory
responses and limiting fibrosis [41].
2.3 Anti-inflammatory action
Evidence that ghrelin exerts anti-inflammatory actions has
been accumulating. Ghrelin suppresses the production of
proinflammatory cytokines, including IL-1β,I L - 6 ,a n d
TNF-α both in vitro [5, 42] and in vivo [43–45]. In clinical
trials, daily administration of ghrelin for 3 weeks decreased
inflammatory cytokine levels and neutrophil density in
sputum from patients with chronic respiratory infections
[46]. In contrast, ghrelin induces the anti-inflammatory
cytokine IL-10 [43, 47].
Ghrelin inhibits the activation of nuclear factor-κB
(NF-κB), a transcription factor known to control the
production of multiple proinflammatory cytokines during
inflammatory insults [42, 44, 47]. Although the molecular
mechanisms and cellular targets mediating ghrelin inhibi-
tion of NF-κB activation remain to be determined, the
vagus nerve may play an important role in the ghrelin-
mediated inhibition of proinflammatory cytokine release
[44, 48]. Cachexia and muscular wasting occur via protein
degradation by the ubiquitin–proteasome pathway [49].
Two muscle-specific ubiquitin ligases, muscle RING-
finger protein-1 (MuRF1) and atrogin-1/muscle atrophy F-
box (MAFbx), are upregulated under catabolic conditions.
NF-κB activation may regulate skeletal muscle proteasome
expressionandprotein degradation.The elevationsinMuRF1
and MAFbx expression seen in skeletal muscle after thermal
injury, arthritis, and dexamethasone administration were
normalized, attenuated, and prevented, respectively, by
ghrelin or GHS administration [50–52]. IGF-1 prevents the
expression of MuRF1 and MAFbx by inhibiting Forkhead
box O transcription factors via stimulation of the
phosphatidylinositol-3-kinase (PI3K)/Akt pathway. The
IGF-1 receptor triggers activation of several intracellular
kinases, including PI3K [53]. Thus, the effects of ghrelin on
NF-κB activation and IGF-1 synthesis are favorable for
minimizing inflammatory responses and sarcopenia in
patients with cachexia.
2.4 Other actions
The role of ghrelin in stimulating gastric emptying and acid
secretion is well-established [54]. This effect may ameliorate
gastrointestinal symptoms in patients with anorexia–cachexia
syndrome. Ghrelin also increases endogenous nitric oxide
release [55, 56], which may influence the orexigenic and
anti-inflammatory actions of ghrelin [57, 58]. These qualities
may be important in the treatment of cachexia.
3 Plasma ghrelin levels in cachexia
Plasma ghrelin levels are elevated in cachectic conditions
caused by a variety of underlying disorders [59–63].
Although this phenomenon has been called “ghrelin
resistance,” these elevations may be a compensatory
response reflecting the negative energy balance state. While
there is usually an inverse relationship between plasma
ghrelin levels and body mass index (BMI), no significant
difference in ghrelin levels between normal subjects and
cachectic patients after matching for BMI. In patients with
end-stage renal disease (ESRD), conflicting results (i.e.,
increases [64–66], decreases [67], or no change [67, 68])
for circulating ghrelin concentrations have been reported
[69]. Aygen et al. recently reported elevations in both
ghrelin and des-acyl ghrelin in ESRD patients undergoing
hemodialysis in comparison to age-matched healthy con-
trols [65]. Iglesias et al. indicated that patients undergoing
hemodialysis possessed similar ghrelin concentrations to
the control group; only peritoneal dialysis patients exhibited
significantly lower ghrelin concentrations at baseline than
those found in patients on conservative management [67].
These conflicting results are due, at least in part, to cross-
sectional studies using different ghrelin assays that com-
pared patients with different residual renal functions, ages,
genders, and nutritional status. Residual renal function may
affect the metabolism and clearance of ghrelin. Longitudi-
nal studies following patients with renal disease using
ghrelin assays measuring both ghrelin and des-ghrelin are
required to determine the pathophysiologic role of ghrelin
in cachexia associated with ESRD. Post-hemodialysis
serum ghrelin levels are significantly lower than pre-
J Cachexia Sarcopenia Muscle (2010) 1:169–176 171hemodialysis ghrelin levels, supporting the view that
ghrelin is cleared by hemodialysis [65, 69, 70].
4 Clinical studies
Trials seeking to apply the effects of ghrelin to the
treatment of cachexia have been expanding. These studies
have sought to evaluate ghrelin as a treatment for patients
with the cachexia associated with CHF, COPD, cancer,
ERSD, etc. Cachexia, which manifests as excessive weight
loss in the setting of an underlying chronic disease [71], is
typically associated with anorexia as a major cause of
weight loss. Weight loss and decreased appetite are the
major causes of morbidity and mortality in patients with
anorexia–cachexia syndrome. There is an immediate need
for effective, well-tolerated treatments to stimulate appetite
[72], prompting several trials to explore the application of
ghrelin as a treatment for patients with cachexia.
4.1 CHF cachexia
Ghrelin induces a positive energy balance state through
both GH-dependent and -independent mechanisms and has
protective cardiovascular effects [73]. GH treatment may be
especially useful in a subgroup of patients with cardiac
cachexia [74]. Ghrelin stimulates food intake, induces
adiposity, regulates the central nervous system to decrease
sympathetic nerve outflow, and inhibits apoptosis of
cardiomyocytes and endothelial cells in a GH-independent
manner. Nagaya et al. investigated the effects of ghrelin on
cardiac cachexia in patients with CHF [36] (Table 1). Daily
administration of ghrelin for 3 weeks increased both food
intake and body weight. This study also demonstrated
improvements in patient exercise capacity, muscle wasting,
and left ventricular function. Ghrelin treatment also resulted
in significantly decreased plasma norepinephrine levels.
Although this study was neither randomized nor placebo-
controlled, the eight CHF patients who did not receive
ghrelin (control group) were followed to rule out any time-
course effects during hospitalization. None of the afore-
mentioned parameters changed in patients with CHF who
did not receive ghrelin therapy. Further studies will be
necessary to identify the pathways involved in this ghrelin
effect and to determine the best therapeutic strategies for
ghrelin use to combat the wasting process found in cardiac
cachexia [74]. Clinical trials are currently attempting to
reproduce these data in a double-blind, placebo-controlled
fashion.
4.2 COPD cachexia
Patients with COPD often exhibit some degree of cachexia
[75], which is an independent risk factor for mortality in
COPD; GH treatment increases muscle mass in such
patients. COPD and CHF are both associated with multiple
pathophysiological disturbances, including anemia and
neurohormonal activation [76]. In COPD patients, ghrelin
exhibits anti-inflammatory effects. Chronic respiratory
infections, characterized by neutrophil-dominant airway in-
flammation, lead to end-stage cachexia [77]. The cytotoxicity
of accumulated neutrophils against bronchial and alveolar
epithelial cells induces a deterioration of pulmonary function
in COPD, resulting in excess energy expenditure and weight
loss in patients. Intravenous ghrelin treatment for 3 weeks
reduced both neutrophil counts in sputum samples and the
volume of sputum, suggesting suppression by ghrelin of
excess neutrophilic influx [46].
An open-label pilot study examined the ability of ghrelin
to improve cachexia and functional capacity in patients
with COPD; ghrelin was administered intravenously for
3 weeks to seven cachectic patients with COPD [18].
Repeated ghrelin administration significantly increased
food intake, body weight, lean body mass, and peripheral
and respiratory muscle strength. Ghrelin treatment amelio-
rated the exaggerated sympathetic nerve activity, as
indicated by marked decreases in plasma norepinephrine
levels. In cachectic patients with COPD, treatment with
ghrelin improved appetite, body composition, muscle
wasting, functional capacity, and sympathetic augmenta-
Table 1 Summary of clinical studies of ghrelin/GHS for cachexia therapy
Diseases Reference Year Study design Ghrelin/GHS administration
CHF [24] 2004 Open-label pilot study Ghrelin, 2 μg/kg b.i.d. for 3 weeks, i.v.
COPD [27] 2005 Open-label pilot study Ghrelin, 2 μg/kg b.i.d. for 3 weeks, i.v.
Cancer cachexia [76] 2004 Acute, randomized, placebo-controlled, cross-over study Ghrelin, 5 pmol/kg/min, i.v., for >180 min
Cancer cachexia [31] 2007 Randomized, placebo-controlled study Anamorelin, 50 mg/day, oral, 12 weeks
Cancer cachexia [77] 2008 Randomized, placebo-controlled, cross-over study Ghrelin, 2 or 8 μg/kg, i.v., for 4 days, once a day
ESRD [79] 2005 Acute, randomized, placebo-controlled, cross-over study Ghrelin, 3.6 nmol/kg, s.c.
ESRD [80] 2009 Randomized, placebo-controlled, cross-over study Ghrelin, 12 μg/kg, s.c., for 1 wk, once a day
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strated that ghrelin increased both appetite and body weight
with an apparent dose-dependent trend towards improved
physical performance (chair stand score) [78]. A larger
clinical trial is currently being conducted to confirm these
data in a double-blind, placebo-controlled fashion. Com-
parisons of this treatment to current standard medications
will be required [76].
4.3 Cancer cachexia
Anorexia, frequently encountered in cancer patients, is one of
the major causes of malnutrition and cachexia in this patient
population. Ghrelin administration resulted in significant
increases inweightand foodintake in rodentmodels of cancer
cachexia [79–81]. In all studies, ghrelin improved both food
intake and weight gain in rodent models. DeBoer et al.
determined that weight gain resulted from a reversal in the
loss of lean body mass, a critical component of cachexia [81].
Several randomized, double-blind placebo-controlled
trials have demonstrated the efficacy and safety of ghrelin
or GHS in patients with cancer-associated cachexia [38, 82,
83]. Nearry et al. performed a randomized, placebo-
controlled, cross-over clinical trial to determine if ghrelin
could stimulate appetite in seven cancer patients with
severe anorexia [82]. Ghrelin infusion resulted in a marked
increase in energy intake in comparison to saline-treated
controls; all patients in the study demonstrated increased
food consumption. The meal appreciation score was also
higher in ghrelin-treated individuals. Strasser et al. detailed
a randomized, double-crossover, phase 1/2 study in patients
with advanced cancer [83]. They infused a low or high dose
of ghrelin or placebo before lunch daily for 4 days in each
course. Nutritional intake or eating-related symptoms did
not differ between the ghrelin- and placebo-treated groups.
More patients, however, preferred ghrelin to placebo at the
middle and end of study, although this finding was not
dose-dependent. In contrast to the results of Neary et al.,
this study did not demonstrate any increases in food intake.
As the patient characteristics and study designs were very
different in the two studies, further investigation will be
required. Garcia et al. performed a randomized, placebo-
controlled trial over a 12-week period using subjects with a
variety of cancer types (predominantly lung cancer).
Anamorelin was infused, which produced an improvement
in total body mass trending toward increased lean mass.
Quality of life, however, was unchanged between the
groups receiving anamorelin and placebo.
An important concern regarding the use of ghrelin in
cancer cachexia is that ghrelin may increase growth factors,
such as GH and IGF-1, to stimulate tumor growth.
Additionally, ghrelin itself may have mitogenic potential.
As far as we know, no in vivo data has examined the
differences in tumor growth after ghrelin or GHS treatment.
Long-term, large-scale clinical trials are required to deter-
mine if ghrelin treatment promotes tumor growth.
4.4 End-stage renal disease
ESRD is a chronic condition frequently associated with
nutritional dysfunction [84]. This type of malnutrition is
highly resistant to intervention and a major predictor of
morbidity and mortality for patients on either peritoneal
dialysis or hemodialysis. Wynne et al. sought to determine if
a single injection of ghrelin could enhance food intake in
patients with evidence of malnutrition receiving maintenance
peritoneal dialysis [85]. Nine peritoneal dialysis patients
exhibiting mild to moderate malnutrition administered either
ghrelin or a saline placebo subcutaneously were examined in
a randomized, double-blind, cross-over protocol. Ghrelin
administration significantly increased mean absolute energy
intake during the study meals and maintained nonsignificant
increases observed in energy intake over the first 24 h
without a subsequent rebound. This research group has
subsequently sought to analyze the efficacy of repeated
ghrelin administrations in malnourished dialysis patients
[86]. They performed a double-blind randomized cross-
over study of a week of daily subcutaneous ghrelin injections
in a group of 12 malnourished dialysis patients. Ghrelin
administration significantly increased appetite, with increases
in energy intake noted at the first study meal. Persistence of
this effect throughout the week was confirmed by food
diaries and final study meals, indicating that daily ghrelin
treatment achieved a sustained positive change in energy
balance in malnourished dialysis patients. In support of this
data, an animal study using a nephrectomized rat model of
renal cachexia demonstrated that daily treatment for 2 weeks
with ghrelin or two GHS agents (BIM-28125 and BIM-
28131) resulted in increased food intake, improved lean
body mass accrual, and decreased circulating inflammatory
cytokines [25]. Long-term studies are needed to demonstrate
the efficacy in improving appetite, weight gain, lean body
mass, and quality of life.
4.5 Others
Ghrelin treatment has also been applied to other causes of
anorexia, sarcopenia, and emaciation, including anorexia
nervosa [87], functional dyspepsia [88], aging [21], post-
gastrectomy anorexia [22], esophagectomy [23], chemother-
apy [89, 90], and thermal injury [91]. In addition, the effects
of ghrelin mimetics were examined in age-dependent
sarcopenia [21, 32]. These applications certainly provide
additional insight into the successful treatment of cachexia, a
wasting syndrome developing in the setting of a variety of
chronic illnesses.
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Ghrelin exhibits anti-cachectic effects in a number of
animal and human studies. Ghrelin treatment is safe and
well-tolerated. Several larger-scale clinical trials are cur-
rently attempting to reproduce these effects for the
treatment of cachexia, including that associated with CHF,
cancer, COPD, and ESRD. Long-term, large-scale trials are
eagerly awaited to determine if ghrelin is an effective
therapy for cachexia.
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